Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Beats Expectations By $0.05 EPS

by · The Markets Daily

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05, Zacks reports. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded down $0.01 during midday trading on Thursday, reaching $13.24. The company’s stock had a trading volume of 194,439 shares, compared to its average volume of 760,410. The firm has a 50 day moving average price of $13.24 and a two-hundred day moving average price of $13.70. Stoke Therapeutics has a fifty-two week low of $3.77 and a fifty-two week high of $17.58. The firm has a market capitalization of $697.06 million, a price-to-earnings ratio of -6.08 and a beta of 0.95.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on STOK. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $20.83.

Read Our Latest Analysis on Stoke Therapeutics

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Read More